Histone deacetylase inhibitors in APL and beyond

K. Petrie, N. Prodromou, A. Zelent

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Scopus citations

Abstract

In recent years the study of chemical modifications to chromatin and their effects oncellular processes has become increasinglyimportant inthe field of cancer research. Disruptions to the normal epigenetic pattern of the cell can serve as biomarkers and are important determinants of cancer progression. Accordingly, drugs that inhibit the enzymes responsible for modulating these epigenetic markers, in particular histone deacetylases, are the focus of intense research and development. In this chapter we provide an overview of class I and II histone deacetylases as well as a guide to the diverse types of histone deacetylase inhibitors and their activities in the context of APL. We also discuss the rationale for the use of histone deacetylase inhibitors in combination therapy for the treatment of cancer and the current status of clinical trials.

Original languageEnglish (US)
Title of host publicationAcute Promyelocytic Leukemia
Subtitle of host publicationMolecular Genetics, Mouse Models and Targeted Therapy
PublisherSpringer Verlag
Pages157-203
Number of pages47
ISBN (Print)3540345922, 9783540345923
DOIs
StatePublished - 2007

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume313
ISSN (Print)0070-217X

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Histone deacetylase inhibitors in APL and beyond'. Together they form a unique fingerprint.

  • Cite this

    Petrie, K., Prodromou, N., & Zelent, A. (2007). Histone deacetylase inhibitors in APL and beyond. In Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy (pp. 157-203). (Current Topics in Microbiology and Immunology; Vol. 313). Springer Verlag. https://doi.org/10.1007/978-3-540-34594-7_10